As each SMARCA4/KRAS co-mutated treatment analysis in this review showed a statistically worse OS or PFS than SMARCA4 WT/KRAS-mutated patients, a prospective comprehensive immune cell analysis could be considered for SMARCA4-mutated and co-mutated SMARCA4/KRAS patients to understand better how these mutations and co-mutations impact the tumor microenvironment. The gene discussed is SMARCA4; the disease is neoplasm.